Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02SVQ
|
|||
| Former ID |
DIB004458
|
|||
| Drug Name |
HBI-3000
|
|||
| Synonyms |
Sulcardine; Multi-ion channel blocker (oral, arrhythmia), SIMM; Multi-ion channel blocker (oral/iv, arrhythmia), HUYA
Click to Show/Hide
|
|||
| Indication | Heart arrhythmia [ICD-11: BC65; ICD-10: I49, I49.8] | Phase 2 | [1] | |
| Atrial fibrillation [ICD-11: BC81.3; ICD-10: I48] | Phase 1 | [2] | ||
| Company |
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Calcium channel unspecific (CaC) | Target Info | Blocker | [3] |
| Potassium channel unspecific (KC) | Target Info | Blocker | [3] | |
| Sodium channel unspecific (NaC) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Dopaminergic synapse | |||
| Reactome | Interaction between L1 and Ankyrins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01235156) Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions. U.S. National Institutes of Health. | |||
| REF 2 | Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. | |||
| REF 3 | Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.